BioWa Receives U.S. Patent for Potelligent(TM) Technology

Strategic Insights -

BioWa, a Princeton-based biotech company, has received a U.S. patent for its proprietary Potelligent(TM) technology, which enhances antibody-dependent cellular cytotoxicity (ADCC) in therapeutic antibodies. The patent, granted by the U.S. Patent & Trademark Office, covers a fucosyltransferase-deficient host cell for producing antibodies with high ADCC activity. This achievement positions Potelligent(TM) technology as a dominant leader in defucosylation technology, allowing for the stable production of 100% fucose-free antibodies.

Key Takeaways:

  • The U.S. patent (U.S. 6,946,292) covers a fucosyltransferase-deficient host cell for producing antibodies with high ADCC activity, a critical mechanism in eliminating tumor cells.
  • Potelligent(TM) technology has been demonstrated to enhance ADCC up to 100 fold in vitro, making it a promising approach for developing more efficacious and potent antibodies.
  • BioWa has built its patent portfolio to support its ongoing antibody technology platform business, with pending applications covering various solutions, including RNAi and enzymatic approaches.
  • The company continues to develop ADCC-enhanced monoclonal antibody-based therapeutics for cancer, asthma, and other life-threatening diseases.
  • BioWa has collaborations with Biogen Idec, Inc. and Medarex, Inc. to develop and license Potelligent(TM) technology.
  • Potelligent(TM) technology allows for the stable production of 100% fucose-free antibodies, which have shown greater tumor cell killing activity and potential for expanded responding patient populations.

Statistics:

  • 100 fold increase in ADCC activity in vitro using Potelligent(TM) technology.
  • 100% fucose-free antibodies produced using Potelligent(TM) technology.
  • 6,946,292 - U.S. patent identifier for the Potelligent(TM) technology patent.
  • 2001 - Year the patent application was filed in the U.S. Patent Office.
  • 2003 - Year the patent was granted.

Sources:

  • BioWa, Inc.
  • Kyowa Hakko Kogyo Co., Ltd.
  • U.S. Patent & Trademark Office
  • ASIA PULSE 18-10 2003